

Antonio Sica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6387581/publications.pdf>

Version: 2024-02-01

59
papers

45,472
citations

81434

41
h-index

162838

57
g-index

59
all docs

59
docs citations

59
times ranked

61162
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunosenescence, Inflammaging, and Frailty: Role of Myeloid Cells in Age-Related Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 123-144.	2.9	40
2	Inflammaging and Osteoarthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 222-238.	2.9	67
3	Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective. <i>Cancers</i> , 2022, 14, 510.	1.7	7
4	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 829-841.	4.8	21
5	Heme catabolism by tumor-associated macrophages controls metastasis formation. <i>Nature Immunology</i> , 2021, 22, 595-606.	7.0	59
6	Regulation of PD-L1 Expression by NF- κ B in Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 584626.	2.2	179
7	Frailty in Rheumatic Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 576134.	2.2	40
8	Immunometabolic Status of COVID-19 Cancer Patients. <i>Physiological Reviews</i> , 2020, 100, 1839-1850.	13.1	20
9	The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6866.	1.8	20
10	Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5845.	1.8	51
11	Influence of Innate Immunity on Cancer Cell Stemness. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3352.	1.8	20
12	Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages. , 2020, 8, e000489.		30
13	Tumor-Derived Prostaglandin E2 Promotes p50 NF- κ B-Dependent Differentiation of Monocytic MDSCs. <i>Cancer Research</i> , 2020, 80, 2874-2888.	0.4	81
14	Oncolytic virotherapy: new weapon for breast cancer treatment. <i>Ecancermedalscience</i> , 2020, 14, 1149.	0.6	12
15	A Proteomic Analysis of GSD-1a in Mouse Livers: Evidence for Metabolic Reprogramming, Inflammation, and Macrophage Polarization. <i>Journal of Proteome Research</i> , 2019, 18, 2965-2978.	1.8	8
16	Myeloid-Derived Suppressor Cells: Ductile Targets in Disease. <i>Frontiers in Immunology</i> , 2019, 10, 949.	2.2	77
17	Membrane Cholesterol Regulates Macrophage Plasticity in Cancer. <i>Cell Metabolism</i> , 2019, 29, 1238-1240.	7.2	11
18	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	2.0	151

#	ARTICLE	IF	CITATIONS
19	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. <i>Cancer Treatment Reviews</i> , 2019, 75, 39-51.	3.4	124
20	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 1938-1951.	0.4	58
21	Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3K/Î³ Inhibitor RP6530. <i>Clinical Cancer Research</i> , 2019, 25, 1098-1112.	3.2	69
22	Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. <i>Cell Stress</i> , 2019, 3, 284-294.	1.4	40
23	Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy. <i>FEBS Journal</i> , 2018, 285, 717-733.	2.2	45
24	Protumor Steering of Cancer Inflammation by p50 NF-Î³ Enhances Colorectal Cancer Progression. <i>Cancer Immunology Research</i> , 2018, 6, 578-593.	1.6	38
25	Metabolic influence on the differentiation of suppressive myeloid cells in cancer. <i>Carcinogenesis</i> , 2018, 39, 1095-1104.	1.3	24
26	Tumor-associated myeloid cells as guiding forces of cancer cell stemness. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1025-1036.	2.0	42
27	Metabolic regulation of suppressive myeloid cells in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2017, 35, 27-35.	3.2	27
28	Myeloid suppressor cells in cancer and autoimmunity. <i>Journal of Autoimmunity</i> , 2017, 85, 117-125.	3.0	154
29	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. <i>Journal of Hepatology</i> , 2017, 66, 102-115.	1.8	130
30	Editorial. <i>Current Opinion in Pharmacology</i> , 2017, 35, vii-ix.	1.7	0
31	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. <i>Nature Communications</i> , 2016, 7, 12150.	5.8	2,076
32	Macrophage polarization in pathology. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 4111-4126.	2.4	487
33	RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopenia. <i>Cancer Cell</i> , 2015, 28, 253-269.	7.7	154
34	Molecular and epigenetic basis of macrophage polarized activation. <i>Seminars in Immunology</i> , 2015, 27, 237-248.	2.7	208
35	Macrophage plasticity and polarization in liver homeostasis and pathology. <i>Hepatology</i> , 2014, 59, 2034-2042.	3.6	359
36	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. <i>Immunity</i> , 2014, 41, 14-20.	6.6	4,638

#	ARTICLE	IF	CITATIONS
37	Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. <i>Cancer Cell</i> , 2014, 25, 846-859.	7.7	1,033
38	Macrophage plasticity and polarization in tissue repair and remodelling. <i>Journal of Pathology</i> , 2013, 229, 176-185.	2.1	1,868
39	Hypoxia-mediated regulation of macrophage functions in pathophysiology. <i>International Immunology</i> , 2013, 25, 67-75.	1.8	69
40	Macrophage plasticity and polarization: in vivo veritas. <i>Journal of Clinical Investigation</i> , 2012, 122, 787-795.	3.9	4,755
41	Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). <i>Cancer Microenvironment</i> , 2012, 5, 133-149.	3.1	81
42	Macrophages in cancer and infectious diseases: the "good" and the "bad". <i>Immunotherapy</i> , 2011, 3, 1185-1202.	1.0	27
43	Macrophages, innate immunity and cancer: balance, tolerance, and diversity. <i>Current Opinion in Immunology</i> , 2010, 22, 231-237.	2.4	1,270
44	Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κ B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 14978-14983.	3.3	551
45	Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. <i>Human Immunology</i> , 2009, 70, 325-330.	1.2	304
46	A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. <i>Blood</i> , 2009, 114, 901-914.	0.6	306
47	The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 1-9.	2.0	866
48	Cancer-related inflammation. <i>Nature</i> , 2008, 454, 436-444.	13.7	9,279
49	Macrophage polarization in tumour progression. <i>Seminars in Cancer Biology</i> , 2008, 18, 349-355.	4.3	1,026
50	Altered macrophage differentiation and immune dysfunction in tumor development. <i>Journal of Clinical Investigation</i> , 2007, 117, 1155-1166.	3.9	1,031
51	A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective) Tj ETQq1 1 0.784314 ggBT /Over 0.6 690	0.6	690
52	p50 Nuclear Factor- κ B Overexpression in Tumor-Associated Macrophages Inhibits M1 Inflammatory Responses and Antitumor Resistance. <i>Cancer Research</i> , 2006, 66, 11432-11440.	0.4	397
53	Macrophage Polarization Comes of Age. <i>Immunity</i> , 2005, 23, 344-346.	6.6	1,035
54	Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. <i>Seminars in Cancer Biology</i> , 2004, 14, 155-160.	4.3	174

#	ARTICLE	IF	CITATIONS
55	The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology, 2004, 25, 677-686.	2.9	5,272
56	Regulation of the Chemokine Receptor CXCR4 by Hypoxia. Journal of Experimental Medicine, 2003, 198, 1391-1402.	4.2	778
57	Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 2002, 23, 549-555.	2.9	4,494
58	Autocrine Production of IL-10 Mediates Defective IL-12 Production and NF- κ B Activation in Tumor-Associated Macrophages. Journal of Immunology, 2000, 164, 762-767.	0.4	400
59	Bacterial Lipopolysaccharide Rapidly Inhibits Expression of CCR Chemokine Receptors in Human Monocytes. Journal of Experimental Medicine, 1997, 185, 969-974.	4.2	279